GTHX - Why Is Breast Cancer-Focused G1 Therapeutics Stock Trading Lower Today? | Benzinga
G1 Therapeutics Inc (NASDAQ:GTHX) shares are trading lower after the company provided an interim update on the Phase 3 PRESERVE 2 trial of trilaciclib as the first-line treatment of metastatic triple-negative breast cancer (mTNBC).
This clinical trial evaluates trilaciclib combined with gemcitabine and carboplatin as a first-line treatment for mTNBC. The independent Data Monitoring Committee (DMC) overseeing the trial has recommended it continue to the final analysis.
In its third quarter 2023 earnings release, G1 said it expected the interim OS analysis to be conducted by its data monitoring committee in the first quarter of 2024.
If the trial meets the interim analysis stopping rule, it will be unblinded, and